Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiles of CD34+ cells from patients with myelodysplastic syndrome CAA or AML

ABSTRACT: To identifying candidate genes which may assist in furthering our knowledge of the mechanisms of the development and progression of MDS AML or CAA. Or finding biomarkers in the future, facilitating the diagnosis of MDS, AML or CAA. Gene expression profiles in the hematopoietic cells of MDS patients have been studied using microarray

ORGANISM(S): Homo sapiens

PROVIDER: GSE107968 | GEO | 2017/12/13

SECONDARY ACCESSION(S): PRJNA422058

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Differential Gene Expression Profiles in CD34+ Myelodysplastic Syndrome Marrow cells to Disease Subtype and Progression

Project description:Microarray analysis with 40,000 cDNA gene chip arrays determined differential gene expression profiles (GEPs) in CD34+ marrow cells from myelodysplastic syndrome (MDS) patients compared to normal individuals. Using focused bioinformatics analyses, we found 1175 genes significantly differentially expressed by MDS vs Normal, requiring a minimum of 39 genes to separately classify these patients. Major GEP differences were demonstrated between Normal and MDS patients and between several MDS subgroups: (1) those whose disease remained stable (sMDS) and those who subsequently transformed (tMDS) to acute myeloid leukemia (AML); (2) between del(5q) and other MDS patients. A 6-gene ‘poor risk’ signature was defined which was associated with AML transformation and provided additive prognostic information for IPSS Intermediate-1 patients. Over-expression of genes generating ribosomal proteins and for other signaling pathways was demonstrated in the tMDS patients. Comparison of del(5q) to the remaining MDS patients showed 1924 differentially expressed genes, with under-expression of 1014 genes, 11 of which were within the 5q31-32 Commonly Deleted Region. These data demonstrated (1) GEPs distinguishing MDS patients from normal and between those with differing clinical outcomes (tMDS vs sMDS) and cytogenetics [eg, del(5q)] ; and (2) molecular criteria refining prognostic categorization and associated biologic processes in MDS. Gene expression profiles from CD34+ cells of 35 MDS subjects and 6 Normals were compared.

2009-10-31 | E-GEOD-18366 | biostudies-arrayexpress

Differential Gene Expression Profiles in CD34+ Myelodysplastic Syndrome Marrow cells to Disease Subtype and Progression

2009-11-01 | GSE18366 | GEO

Gene expression profiles of CD34+ cells from patients with myelodysplastic syndrome CAA or AML

Project description:Gene expression profiles of CD34+ cells from patients with myelodysplastic syndrome CAA or AML

| PRJNA422058 | ENA

Gene expression profiling of pediatric myelodysplastic syndrome (MDS) characterizes disease subtype and time to progression into acute myeloid leukemia (AML)

Project description:Identification of relevant subgroups in childhood MDS patients by gene expression analysis and gene involve in progression into AML Class comparison between different subgroups of pediatric MDS (class risk, classification subtype)

2012-02-29 | E-GEOD-29326 | biostudies-arrayexpress

Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukaemia (AML)

Project description:A 10K cDNA microarray was used to compare neutrophil RNA from 21 MDS patient and 2 AML patients to pooled neutrophil RNA from 7 healthy controls.

2005-01-09 | E-GEOD-971 | biostudies-arrayexpress

Gene expression profiling of pediatric myelodysplastic syndrome (MDS) characterizes disease subtype and time to progression into acute myeloid leukemia (AML)

Project description:Identification of relevant subgroups in childhood MDS patients by gene expression analysis and gene involve in progression into AML

2012-02-29 | GSE29326 | GEO

Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukaemia (AML)

Project description:A 10K cDNA microarray was used to compare neutrophil RNA from 21 MDS patient and 2 AML patients to pooled neutrophil RNA from 7 healthy controls. Keywords: repeat sample

2005-01-10 | GSE971 | GEO

High expression of circZBTB46 predicts poor prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia

Project description:This study aimed to find the functional circular RNA and further analyze its biological and clinical significance in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients.The circRNAs profiles were analyzed using the Arraystar human circRNA microarray with bone marrow samples from 5 MDS patients, 5 AML patients and 4 controls. Real-time quantitative polymerase chain reaction was carried on circZBTB46 in bone marrow samples from 124 MDS patients, 116 AML patients and 37 controls, and subsequently associated with clinicopathological characteristics and survival of MDS and AML patients.Furthermore, functional studies were conducted by silencing and rescuing/increasing circZBTB46 expression in SKM-1, THP-1 and K562 cell lines. Our results suggested the essential role of circZBTB46 in the progression of MDS and AML, and might be a poor indicator of hematological malignancies.

2020-12-17 | GSE163386 | GEO

PAK1 is a Therapeutic Target in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Project description:Poor clinical outcome of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) has been attributed to failure of current chemotherapeutic regimens to target leukemic stem cells. We recently identified p21-activated kinase (PAK1) as a downstream effector molecule of H2.0-like homeobox (HLX), a gene functionally relevant for AML pathogenesis. In this study, we find that inhibition of PAK1 activity by small molecule inhibitors or by RNA interference leads to profound leukemia-inhibitory effects both in vitro and in vivo. Inhibition of PAK1 induces differentiation and apoptosis of AML cells through downregulation of MYC oncogene and a core network of MYC target genes. Moreover, we find that PAK1 up-regulation occurs during disease progression and is relevant for patient survival in MDS. Importantly, we find that inhibition of PAK1 inhibits primary human leukemic cells including immature leukemic stem cell-enriched populations. Our studies highlight PAK1 as a novel target in AML and MDS, and support the use of PAK1 inhibitors as a therapeutic strategy in these diseases. To obtain insight into the molecular mechanism for the induction of apoptosis and differentiation resulting from PAK1 inhibition in AML, we performed gene expression microarrays following treatment with either IPA-3 or FRAX-597. RNA was isolated from THP-1 cells after 5 hours of treatment with IPA-3 (6 ug/mL), FRAX-597 (2 ug/mL) or an equal volume of DMSO using Trizol Reagent (Invitrogen).

2015-07-11 | E-GEOD-70791 | biostudies-arrayexpress

Transcription profiling of CD34+ cells from the bone marrow of Myelodysplastic syndrome patients and healthy controls

Project description:In order to gain insight into the molecular pathogenesis of the myelodysplastic syndromes (MDS), we performed global gene expression profiling and pathway analysis on the hematopoietic stem cells (HSC) of 183 MDS patients as compared with the HSC of 17 healthy controls. The most significantly deregulated pathways in MDS include interferon signaling, thrombopoietin signaling and the Wnt pathway. Among the most significantly deregulated gene pathways in early MDS are immunodeficiency, apoptosis and chemokine signaling, whereas advanced MDS is characterized by deregulation of DNA damage response and checkpoint pathways. We have identified distinct gene expression profiles and deregulated gene pathways in patients with del(5q), trisomy 8 or â??7/del(7q). Patients with trisomy 8 are characterized by deregulation of pathways involved in the immune response, patients with â??7/del(7q) by pathways involved in cell survival, whilst patients with del(5q) show deregulation of integrin signaling and cell cycle regulation pathways. This is the first study to determine deregulated gene pathways and ontology groups in the HSC of a large group of MDS patients. The deregulated pathways identified are likely to be critical to the MDS HSC phenotype and give new insights into the molecular pathogenesis of this disorder thereby providing new targets for therapeutic intervention. 183 patients with MDS patients and 17 healthy controls were included in the study. Bone marrow samples were obtained and CD34+ cells isolated from MDS patients and healthy controls. Samples were hybridized to Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays

2010-03-24 | E-GEOD-19429 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data